KOPS - The Institutional Repository of the University of Konstanz

Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice

Aufgrund von Vorbereitungen auf eine neue Version von KOPS, können am Montag, 6.2. und Dienstag, 7.2. keine Publikationen eingereicht werden. (Due to preparations for a new version of KOPS, no publications can be submitted on Monday, Feb. 6 and Tuesday, Feb. 7.)

Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice

Cite This

Files in this item

Checksum: MD5:8fa1c077f85fa5d2e0b4bfc4ade00724

GIL, Joana MAC, Marcel LEIST, Natalija POPOVIC, Patrik BRUNDIN, Åsa PETERSÉN, 2004. Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice. In: BMC Neuroscience. 5, 17. eISSN 1471-2202. Available under: doi: 10.1186/1471-2202-5-17

@article{Gil2004Asial-7115, title={Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice}, year={2004}, doi={10.1186/1471-2202-5-17}, volume={5}, journal={BMC Neuroscience}, author={Gil, Joana MAC and Leist, Marcel and Popovic, Natalija and Brundin, Patrik and Petersén, Åsa}, note={Article Number: 17} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/7115"> <dc:creator>Gil, Joana MAC</dc:creator> <dc:contributor>Gil, Joana MAC</dc:contributor> <dc:rights>terms-of-use</dc:rights> <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/7115/1/gil_04_asialoEPO.pdf"/> <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/7115/1/gil_04_asialoEPO.pdf"/> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Petersén, Åsa</dc:contributor> <dc:creator>Petersén, Åsa</dc:creator> <dc:contributor>Brundin, Patrik</dc:contributor> <dc:language>eng</dc:language> <dc:format>application/pdf</dc:format> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:31:35Z</dcterms:available> <dcterms:title>Asialoerythropoetin is not effective in the R6/2 line of Huntington's disease mice</dcterms:title> <dc:creator>Popovic, Natalija</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Brundin, Patrik</dc:creator> <dcterms:bibliographicCitation>First publ. in: BMC Neuroscience 5 (2004), 17, pp. 1-10</dcterms:bibliographicCitation> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/7115"/> <dcterms:issued>2004</dcterms:issued> <dc:creator>Leist, Marcel</dc:creator> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-24T17:31:35Z</dc:date> <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/> <dc:contributor>Popovic, Natalija</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <dc:contributor>Leist, Marcel</dc:contributor> <dcterms:abstract xml:lang="eng">Background: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. Both excitotoxicity and oxidative stress have been proposed to play important roles in the pathogenesis of HD. Since no effective treatment is available, this study was designed to explore the therapeutic potential of erythropoietin (EPO), a cytokine that has been found to prevent excitotoxicity, and to promote neurogenesis. To avoid the side effects of a raised hematocrit, we used asialoerythropoietin (asialoEPO), a neuroprotective variant of EPO that lacks erythropoietic effects in mice. R6/2 transgenic HD mice were treated with this cytokine from five to twelve weeks of age. Results: We provide new evidence that cell proliferation in the dentate gyrus of the R6/2 hippocampus is reduced by 50% compared to wild-type littermate controls. However, we found that the asialoEPO treatment did not affect the progression of motor symptoms, weight loss or the neuropathological changes. Furthermore, cell proliferation was not enhanced. Conclusions: We conclude that the chosen protocol of asialoEPO treatment is ineffective in the R6/2 model of HD. We suggest that reduced hippocampal cell proliferation may be an important and novel neuropathological feature in R6 HD mice that could be assessed when evaluating potential therapies.</dcterms:abstract> </rdf:Description> </rdf:RDF>

Downloads since Oct 1, 2014 (Information about access statistics)

gil_04_asialoEPO.pdf 810

This item appears in the following Collection(s)

Search KOPS


My Account